打开APP

Forest向FDA提交美金刚ER/多奈哌齐FDC 新药申请

  1. Forest Lab
  2. 多奈哌齐
  3. 美金刚
  4. 阿尔茨海默型老年痴呆症

来源:生物谷 2014-03-06 08:56

森林实验室向FDA提交缓释美金刚/多奈哌齐组合药物新药申请(NDA),该药用于中度至重度阿尔茨海默型老年痴呆症治疗。

2014年3月5日讯 /生物谷BIOON/ --森林实验室(Forest Lab)和合作伙伴Adamas制药公司3月4日宣布,已向FDA提交了缓释美金刚(memantine ER)+多奈哌齐(donepezil)固定剂量组合产品(FDC)的新药申请(NDA),该药开发用于中度至重度阿尔茨海默型老年痴呆症(Alzheimer's type dementia)的治疗。

美金刚(memantine)和多奈哌齐(donepezil)联合用药,是用于阿尔茨海默氏症患者中度至重度老年痴呆症的一套行之有效的治疗方案。缓释美金刚ER/多奈哌齐FDC,有助于帮助减轻患者日常用药的负担,并改善患者的依从性和合规(compliance,即遵医行为)。

美金刚ER/多奈哌齐FDC是一种每日一次的口服胶囊,适用于目前正在服用美金刚(10mg每日2次,或28mg缓释)和多奈哌齐(10mg)的患者。此外,该胶囊可以被打开,并允许撒在苹果酱中,以方便可能有吞咽困难的患者。

美金刚ER/多奈哌齐FDC的新药申请包括2种给药剂量,28mg/10mg和14mg/10mg,后者可用于有严重肾功能损害的患者。

目前,美金刚缓释(memantine ER)胶囊已以品牌名NAMENDA XR上市销售,适用于中度至重度阿尔茨海默型老年痴呆的治疗。多奈哌齐品牌名为ARICEPT,适用于轻度至重度阿尔茨海默型老年痴呆的治疗。

上个月,Forest lab与全球第三大仿制药商阿特维斯(Actavis)签订了一份收购协议,交易总额达250亿美元(约每股89.48美元),今日,Forest lab股价收于99.36美元。

通过此次收购,Actavis将获得阿尔茨海默氏症药物Namenda及一些新药如抗抑郁药物Viibryd。分析师称,此次收购将赋予Actavis更多的话语权,与医院和其他医疗护理提供商进行谈判。(生物谷Bioon.com)

英文原文:Forest Labs. Submits NDA For FDC Of Memantine HCl ER And Donepezil HCl

NEW YORK & EMERYVILLE, Calif.--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE:FRX), a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market, and Adamas Pharmaceuticals Inc., a privately held specialty pharmaceutical company, announced Forest’s submission of a New Drug Application (NDA) to the Food and Drug Administration for a fixed-dose combination (FDC) of memantine HCl extended release (ER) and donepezil HCl for the treatment of moderate to severe dementia of the Alzheimer’s type.

“The concurrent use of memantine and donepezil is a well-established treatment option for patients with moderate to severe dementia related to Alzheimer’s disease. Using the two drugs together appears to provide benefit over using acetylcholinesterase inhibitors alone. Reducing the number of pills by offering patients a fixed-dose combination helps lessen the daily medication burden and could improve patient adherence and compliance,” said Pierre Tariot, MD, at the Banner Alzheimer’s Institute, who has also consulted to both Adamas and Forest.

The memantine ER-donepezil HCl FDC is a once-daily oral capsule for patients currently taking memantine (10 mg twice daily or 28 mg extended-release once-daily) and donepezil 10 mg. In addition, the capsules can be opened to allow the contents to be sprinkled on applesauce to facilitate dosing for patients who may have difficulty swallowing.

The New Drug Application consisted of two dosage strengths, 28mg/10mg (memantine extended release/donepezil) and 14mg/10mg (memantine extended release/donepezil) for patients with severe renal impairment. Memantine ER is the active ingredient in the currently marketed NAMENDA XR?, which is indicated for the treatment of moderate to severe dementia of the Alzheimer’s type. Donepezil is the active ingredient in ARICEPT?, which is indicated for the treatment of mild to severe dementia of the Alzheimer’s type. Forest and Adamas collaborated on the development of the fixed dose combination and Forest will have exclusive US commercialization rights while Adamas will retain exclusive commercialization rights outside of the US. The FDC product is covered by multiple Adamas patents and a Forest patent that extend to 2029.

About Alzheimer’s disease

Alzheimer’s disease is a progressive, neurodegenerative disorder characterized by problems with memory, thinking and behavior that eventually become severe enough to affect daily tasks. An estimated 5.2 million people in the United States are currently living with Alzheimer’s disease. Alzheimer’s disease is the fifth leading cause of death in the United States among those aged 65 and older, and was reported as an underlying cause of death for more than 83,000 Americans in 2010.

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->